NR566 Week 1

NR566 Week 1 Veri NR566 Week 1 fied Solution ### Bisphosphonates - Mechanism: Inhibit both normal and abnormal bone resorption, increasing bone mineral density. - Cautions: Use with caution in patients with renal impairment, heart failure, liver disease, and gastrointestinal problems. - Side Effects: Gastrointestinal and esophageal irritation. - Drugs: - Alendronate (Fosamax) - Risedronate (Actonel) - Ibandronate (Boniva) - Common Side Effects: Esophagitis, arthralgia. - Interactions: Ranitidine. ### Insulin Dosing - Dosage: 0.3 to 0.5 units/kg/day, divided into multiple doses. - Effects: Lowers blood glucose by 20-60 mg/dL. - Special Considerations: Lower doses may be needed during the honeymoon phase or with physical activity. ### Biguanides - Drug: Metformin (Glucophage). - Indication: First-line therapy for most patients with type 2 diabetes. - Treatment Plan: Add a second drug if target blood glucose levels are not met within three months. ### Thiazolidinediones (TZDs) - Drugs: Pioglitazone (Actos), Rosiglitazone (Avandia). - Adverse Reactions: Weight gain, edema, heart failure. ### Sulfonylureas - Drugs: Glipizide, Glyburide, Glimepiride. - Adverse Reactions: Weight gain, hypoglycemia. ### Incretin Drugs - Drugs: Exenatide (Byetta, Bydureon), Liraglutide (Victoza), Sitagliptin (Januvia), Alogliptin (Nesina), Linagliptin (Tradjenta). ### Dipeptidyl Peptidase-4 (DPP-4) Inhibitors